TY - JOUR AB - Modification of protein-based drug carriers with tumor-targeting properties is an important area of research in the field of anticancer drug delivery. To this end, we developed nanoparticles comprised of elastin-like polypeptides (ELPs) with fused poly-aspartic acid chains (ELP-D) displaying DNA aptamers. DNA aptamers were enzymatically conjugated to the surface of the nanoparticles via genetic incorporation of Gene A protein into the sequence of the ELP-D fusion protein. Gene A protein, derived from bacteriophage X174, can form covalent complexes with single-stranded DNA via the latter's recognition sequence. Gene A protein-displaying nanoparticles exhibited the ability to deliver the anticancer drug paclitaxel (PTX), whilst retaining activity of the conjugated Gene A protein. PTX-loaded protein nanoparticles displaying DNA aptamers known to bind to the MUC1 tumor marker resulted in increased cytotoxicity with MCF-7 breast cancer cells compared to PTX-loaded protein nanoparticles without the DNA aptamer modification. AU - Mie,M AU - Matsumoto,R AU - Mashimo,Y AU - Cass,AEG AU - Kobatake,E DO - 10.1007/s11033-018-4467-2 EP - 269 PY - 2019/// SN - 0301-4851 SP - 261 TI - Development of drug-loaded protein nanoparticles displaying enzymatically-conjugated DNA aptamers for cancer cell targeting T2 - Molecular Biology Reports UR - http://dx.doi.org/10.1007/s11033-018-4467-2 UR - https://www.ncbi.nlm.nih.gov/pubmed/30421127 UR - http://hdl.handle.net/10044/1/66185 VL - 46 ER -